Skip to the content

Fibrofind has developed a technology that allows prolonged use of functional precision-cut slices of various human organs tissues applying our technology to liver,  kidney and IPF lung PCS.

Our PCS patented technology is extremely successful. Fibrofind is able to keep human organ slices in intact and active state for 7 days. We have optimised induction of fibrogenesis/fibrosis in normal PCS using a specific set of stimuli, which we are able to readily block using an inhibitor, this providing a positive control for any treatment that you may want us to test.

Our technology platform is detailed in our recently published paper in Hepatology journal that describes the PCLS (Liver) technology and associated outputs

https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.30651

 

In addition to the published model, we are able to lipid load the PCLS thus generating early-stage NASH. Again, drugs can be tested in this context for their ability to reduce steatosis, inflammation or fibrosis.

All of the models are well worked out but how we set up the system to address the activity of a drug/reagent of interest is done in a bespoke manner, based on extensive conversations with you and a clear understanding of what the given drug/reagent is meant to do in the diseased organ you are investigating. We are then able to advise the best way to model the disease of interest in PCLS and how most appropriately to design the study and its outputs to address the pathway that your drug/reagent affects.

Once the PCLS study has been performed for you and the analyses have been carried out (which can involve immunohistochemistry, digital image analysis, qPCR, hydroxyproline assays, MSD measurements of numerous soluble markers, ELISAs and many other types of laboratory outputs) we supply you with a full report and send all of the longitudinally collected PCLS supernatants, paraffin blocks, stained slides, any leftover unstained slides and all frozen samples (RNA/DNA) from the study. Importantly, you hold all of the IP rights to the project while our advice and intellectual input come as part of the service-for-fee.

 

We are able to do both liver and kidney PCS in this context, although we have not yet published any of our kidney data due to a patent filing. In addition, we also offer IPF lung PCS.